Evidence map›Paper›PMID 28415924›Full record

ArticleThe Journal of international medical research2017

An assessment of the current treatment landscape for rheumatology patients in Qatar: Recognising unmet needs and moving towards solutions.

Samar Al Emadi, Mohammed Hammoudeh, Mohamed Mounir, Ruediger B Mueller, Alvin F Wells, Housam Aldeen Sarakbi

Abstract read
In one paragraph

Article in The Journal of international medical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Recommendation for the Management of Spondyloarthritis Patients in Kuwait.Open access rheumatology : research and reviews · 2020
    Article
  5. Patient preferences for rheumatoid arthritis treatment.Current opinion in rheumatology · 2019
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Samar Al Emadi1 Hamad Medical Corporation, Qatar and Weill Cornell Medical College, Qatar.
Mohammed Hammoudeh1 Hamad Medical Corporation, Qatar and Weill Cornell Medical College, Qatar.
Mohamed Mounir2 Pfizer Inc. Gulf and Levant States, UAE.
Ruediger B Mueller3 Kantonsspital St. Gallen, St. Gallen, Switzerland.
Alvin F Wells4 Rheumatology and Immunotherapy Center, Franklin, WI, USA.
Housam Aldeen Sarakbi5 Hamad Medical Corporation, Qatar; Weill Cornell Medical College, Qatar; Mercy Health System, Janesville, Wisconsin, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective This study assessed the mode of application (oral, intravenous or subcutaneous (SC)) currently employed in the treatment of rheumatoid arthritis (RA) in patients from Qatar in comparison with patients' individual preferences for the mode of application of their treatment. Methods This study included 294 RA patients visiting three clinics at the main referral hospital in Qatar who were interviewed using a standard questionnaire to determine their preference of mode of application for their disease-modifying antirheumatic drug (DMARD) treatment in relation to their currently employed mode of application. Results The majority of patients were female (76%), and 93% of male patients and 61% of female patients in the study clinics were of a nationality other than Qatari. The highest patient preference recorded was for an oral therapy (69%), compared with injection (23%) and intravenous (8%) therapy. In total, 85% of patients expressed a preference to remain on oral therapy compared with 63% and 58% of intravenous and SC injection patients indicating a preference to remain on their current method of administration. Conclusions This high preference for oral therapies highlights the considerable need for incorporation of new oral targeted synthetic DMARD therapies into clinical practice within the region.

Indexed as

Administration, CutaneousAdministration, OralAdultAgedAged, 80 and overAntirheumatic AgentsArthritis, RheumatoidCross-Sectional StudiesFemaleHumansInjections, IntravenousMaleMiddle AgedPatient SatisfactionQatarSeverity of Illness IndexAntirheumatic AgentsArabian GulffastingMiddle Eastnovel oral therapiespatient preferencepatient profileQatarRheumatoid arthritisroute of administrationtemperature

Identifiers

PMID28415924
PMCPMC5536653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.